...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: More sites now recruiting for ZEN003694 NCT02705469 trial

If they do have patent protection would they not announce it?

Or perhaps patents require too much information to be divulged to competitors and they want to move along on the trial and get results before they let information???

Anyway, if anybody understands this stuff I like to hear.

Regards

Toinv

Share
New Message
Please login to post a reply